Summary: Cassava Sciences’ phase 3 RETHINK study of simufilam in Alzheimer’s disease was not a
Summary: Cassava Sciences’ Phase 3 trial for Alzheimer’s failed to meet primary or secondary endpoints,
Summary: Cassava Sciences’ Alzheimer’s drug simufilam failed to meet primary, secondary, and exploratory endpoints in
Summary: Cassava Sciences’ Alzheimer’s drug simufilam failed its Phase 3 trial, causing the stock to
Eoneren/E+ via Getty Images Cassava Sciences (NASDAQ:SAVA) crashed nearly 84% following a late-stage trial setback
travellinglight Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer’s disease candidate simufilam
travellinglight/iStock via Getty Images Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer,
travellinglight/iStock via Getty Images A federal registry on clinical trials indicated on Friday that Cassava
Summary: Panax ginseng shows the highest effectiveness in treating Alzheimer’s because it inhibits nitro-oxidative stress,
Summary: Cassava Sciences’ stock is highly shorted, with potential reward tied to the upcoming Phase